**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
João Bessa Silva, Department of Nephrology, Centro Hospitalar Universitário de Santo António (CHUdSA), Porto, Portugal

**Main Body of the Abstract**
Introduction
Studies of sodium-glucose co-transporter 2 inhibitors (SGLT2i) therapy on ATTR kidney and heart disease are scarce and focus wild-type and V122I. In ATTRv, namely V30M, SGLT2i introduction to preserve kidney function or improve cardiorenal syndrome is not an outlined practice. We assessed the safety and clinical evolution, based on a staging score system, of SGLT2i therapy in ATTR V30M amyloidosis

Methods
Patients with biopsy proven ATTR V30M amyloidosis and criteria for SGLT2i started standard dosages. Gillmore score (GS) for ATTR cardiomyopathy, kidney failure risk equation (KFRE) and the renal system score (RSS) of the FASTEX model (Fabry disease) were calculated. We recalculated GS using CKD-EPI creatinine and CKD- EPI cystatin C. Tc-99-DPD scintigraphy was used to estimate heart amyloid load.

Results
Eight patients (4 males) were follow on median of 11,9 months; 3 had positive DPD scintigraphy, all males, who presented with a late-onset of symptoms, echocardiographic features of cardiac amyloidosis, and increased NT-proBNP. Cardiovascular and renal adverse events were absent. Neurogenic bladder was present in 3 patients, 2 had uncomplicated urinary tract infections; 1 had symptomatic hypotension, leading to discontinuation of therapy. Baseline line characteristics and clinical evolution are summarized in table1.

Conclusions
In this pilot study, we evidenced that ATTR V30M patients meet the criteria for SGLT2i therapy. Dysautonomia and neurogenic bladder were not an impediment for therapy. In addition to disease modifying drugs, SGLT2i may improve kidney and cardiovascular outcomes in ATTR V30M amyloidosis, across distinct clinical phenotypes.



Early tolerance of SGLT2i therapy in patients with ATTR V30M amyloidosis: staging and scoring for a standard of care evaluation across different clinical phenotypes PC135 (#399)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.